Copycat Weight-Loss Pill Removed From the Market Amid FDA Crackdown

(MedPage Today) — The FDA announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded semaglutide (Wegovy) weight-loss pill from the market…

Source link : https://www.medpagetoday.com/publichealthpolicy/fdageneral/119806

Author :

Publish date : 2026-02-09 20:19:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Copycat Weight-Loss Pill Removed From the Market Amid FDA Crackdown

Finding a Way to Make Health Technology Work for Us — Not Us for It

Nurses Say They Might Return to Hospitals If Employers Made These Changes

Related Posts

Nurses Say They Might Return to Hospitals If Employers Made These Changes

Finding a Way to Make Health Technology Work for Us — Not Us for It

Science Communication Should Be a Core Competency in Medical Training

Who Is Behind the Mike Tyson Super Bowl Ad?

U.S., Australia Lead the World on Kids’ Food Allergy Rates

Gravitational wave signal proves Einstein was right about relativity

Nurses Say They Might Return to Hospitals If Employers Made These Changes

Copycat Weight-Loss Pill Removed From the Market Amid FDA Crackdown

Finding a Way to Make Health Technology Work for Us — Not Us for It

Science Communication Should Be a Core Competency in Medical Training

Who Is Behind the Mike Tyson Super Bowl Ad?

U.S., Australia Lead the World on Kids’ Food Allergy Rates

Gravitational wave signal proves Einstein was right about relativity

SMC Rejects Sotatercept For Pulmonary Hypertension

Categories

Archives